Sex as a variable in medicines assessment reports for licensing in the European Union. Can gender bias be excluded?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To analyse publically available official reports on the evaluation of European Union (EU) registration of new medicines (aimed at diseases affecting both sexes) in order to address the possibility of gender bias.
Descriptive study reviewing two types of assessment reports corresponding to different EU registration procedures: European Public Assessment Reports (EPARs) for the centralised procedures (399 reports considered from 2001 to 2002 and 2008 to 2009) and Mutual Recognition or Decentralised Public Assessment Reports (MPARs) for the mutual recognition and decentralised procedures (2,704 reports, totality until 2009—inclusive).
Two hundred and twenty-four EPARs fulfilled the study criteria. It can be deduced from those EPARs that women participated in at least one clinical trial in 215 (78.5 %) of the reports. In 49(17.9 %) of the EPARs, the study population is explicitly evaluated according to sex, ten (3.6 %) presenting results disaggregated by sex. Most sex-related differences are in safety and pharmacokinetics; six of the 22 cases (72.7 %) of safety differences and nine of the 23 cases (60.9 %) of pharmacokinetic differences are not discussed. In relation to MPARs, only 2,704 out of 15,621 registries (17 %) were published, which casts doubts on the representativity of the available reports. Those published reflect less participation by women than in the EPARs.
From the incomplete sex-related data made public, it is difficult to conclude on the existence of gender bias in the evidence used for the evaluation of new medicines. It certainly cannot be excluded. It is therefore recommended that compliance with existing guidance for publication of reports is increased, so as to transparently reassure on the issue.
- Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal of the European Union, L 311, 28/11/2001 p. 0067–0128
- Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union, L 136, 30/4/2004 p. 34–57
- Zopf Y, Rabe C, Neubert A et al (2008) Women encounter ADRs more often tan do men. Eur J Clin Pharmacol 64(10):999–1004 CrossRef
- Lippman A (2006) The inclusion of women in clinical trials: are we asking the right questions? Canada women and health protection. Bureau of women’s health and gender analysis, health canada
- Vivek HM, Harlan MK, Cary PG (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720–2726 CrossRef
- Stramba-Badiale M, Priori SG (2005) Gender-specific prescription for cardiovascular diseases? Eur Heart J 26(16):1571–1572 CrossRef
- Rodenburg EM, Stricker BH, Visser LE (2012) Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions. Br J Clin Pharmacol 74(6):1045–1052 CrossRef
- Fleisch J, Fleisch MC, Thürmann PA (2005) Women in early-phase clinical drug trials: have things changed over the past 20 years? Clin Pharmacol Ther 78(5):445–452 CrossRef
- CORDIS: Community Research and Development Information Service. Exclusion from clinical trials harming women’s health [cited 2007-03-08]. Available at: http://cordis.europa.eu/fetch?CALLER=EN_NEWS&ACTION=D&DOC=15&CAT=NEWS&QUERY=013b37a2e348:3ab7:25cf3db4&RCN=27270. Accessed 31 April 2013
- Bartlett C, Doyal L, Ebrahim S et al (2005) The causes and effects of socio-demografic exclusions from clinical trials. NHS R&D HTA Programe. Health Technol Assess 9:1–130
- National Institutes of Health – NIH (2001) NIH Guidelines on the inclusion of women and minorities as subjects in clinical research. Available at: http://grants.nih.gov/grants/funding/women_min/outreach_qa.htm. Accessed 31 April 2013
- Thümmler K, Britton B, Wilhelm K et al. (2009) Data and Information on Women’s Health in the European Union. Faculty of Medicine Carl Gustav Carus. Available at: European Commission, http://ec.europa.eu/health/population_groups/gender/index_en.htm. Accessed 31 April 2013
- Bisilliat J (2001) Introducing the gender perspective in national essential drug programmes. Department of Essential Drugs and Medicines Policy. World Health Organ 78:549–561
- Chilet-Rosell E, Ruiz-Cantero MT, Horga JF (2009) Women’s health and gender-based clinical trials on etoricoxib: methodological gender bias. J Public Health 31:434–435 CrossRef
- Stramba-Badiale M, Fox KM, Priori SG et al (2006) Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 27:994–1005 CrossRef
- Geller SE, Abby K, Pellettieri B et al (2011) Inclusion, Analysis, and Reporting of Sex and Race/Ethnicity in Clinical Trials: Have We Made Progress? J Womens Health 20(3):315–320 CrossRef
- García-Sánchez I (2004) Gender differences in HIV/AIDS. Gac Sanit 18(Supl 2):47–54 CrossRef
- Arenere Mendoza M, Cilveti-Sanchez U, Idopie Tomas A et al (2004) Influence of gender on clinical research. Farm Hosp 28(6):440–444
- Food and Drug Administration (FDA) (2001) Women’s Participation in Clinical Trials and Gender-Related Labeling: A Review of New Molecular Entities Approved 1995–1999. Available at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ParticipatinginClinicalTrials/ucm197788.htm. Accessed 31 April 2013.
- European Medicines Agency (2005) Gender considerations in the Conduct of Clinical Trials. EMEA/CHMP/3916/2005-ICH
- European Medicines Agency (2006) Reflection paper on gender differences in cardiovascular diseases. Doc. Ref. EMEA/CHMP/EWP/498145/2006
- European Medicines Agency (2009) The EMEA transparency policy draft for public consultation. Doc. Ref. EMEA/232037/2009 – rev
- Chilet Rosell E, Ruiz Cantero MT, Laguna-Goya N et al (2010) Recommendations for the study and evaluation of gender differences in clinical trials in Spain. Med Clin (Barc) 135(3):130–134 CrossRef
- Laguna Goya N, de Andrés R-TF (2008) Women participation in clinical trials. A preliminary study in the files of the Spanish Agency for Medicinal Products and Medical Devices. Rev Esp Salud Publica 82:343–350 CrossRef
- European Commission Directorate General for Competition (2009). The Pharmaceutical Sector Inquiry Report. Available at: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html. Accessed 31 April 2013
- Müllner M, Vamvakas S, Rietschel M et al (2007) Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? a review of the database of the European Medicines Agency. Int J Clin Pharmacol Ther 45(9):477–484 CrossRef
- Chen ML, Lee SC, Ng MJ et al (2000) Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 68(5):510–521 CrossRef
- Koren G, Nordeng H, MacLeod S (2013) Gender differences in drug bioequivalence: time to rethink practices. Clin Pharmacol Ther 93(3):260–262 CrossRef
- European Medicines Agency (2010) Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 REV. 1
- European Medicines Agency (2001) Note for Guidance on the Investigation of Bioavailability and Bioequivalence. CPMP/EWP/QWP/1401/98
- European Medicines Agency (2009) EPAR prucalopride (Resolor®), EMEA/H/C/1012
- European Medicines Agency (2008) EPAR febuxostat (Adenuric®), EMEA/H/C/000777
- European Medicines Agency (2001) EPAR lopinavir/ritonavir (Kaletra®), EMEA/H/C/000368
- European Medicines Agency (2008) EPAR etravirine (Intelence®), EMEA/H/C/000900
- European Medicines Agency (2008) EPAR ranolazine (Ranexa®), EMEA/H/C/805
- Sex as a variable in medicines assessment reports for licensing in the European Union. Can gender bias be excluded?
European Journal of Clinical Pharmacology
Volume 70, Issue 5 , pp 519-525
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Clinical trial
- Assessment report for marketing
- Medicines related sex differences
- Gender bias
- Industry Sectors